About Refoxy Pharma
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and elicit unique therapeutic effects. The company is developing a pipeline of therapeutics, with an initial focus on fibrotic disorders, particularly IPF. Refoxy is based in Cologne, Germany.
Press releases
Press
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis
Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF.
New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.
Cologne, Germany, 4 December 2024 – Refoxy Pharmaceuticals GmbH is a preclinical biotech company developing small molecule activators of the
Info & Contact
- E–Mail:
- info@refoxy.com
- Web:
- www.refoxy.com
Address
Refoxy Pharmaceuticals GmbH
c/o Apollo Health Ventures
Schlueterstr. 36
10629 Berlin
c/o Apollo Health Ventures
Schlueterstr. 36
10629 Berlin
In portfolio
30. Jul 2024
Sector
Dr. Christian Kannemeier
Senior Investment Manager